--- type: "firecrawl-provider" description: "EU centralised medicines data from EMA's published data files: authorised medicines (EPAR pages), CHMP and CVMP opinions and withdrawn applications, applications under evaluation, EU orphan designations, EPAR and product documents, and EMA-assessed supply shortages, with EMA attribution on every result." use_when: "EU centralised medicines data from EMA's published data files: authorised medicines (EPAR pages), CHMP and CVMP opinions and withdrawn applications, applications under evaluation, EU orphan designations, EPAR and product documents, and EMA-assessed supply shortages, with EMA attribution on every result." categories: "Life sciences" capabilities: 6 credits_per_call: 5 --- # European Medicines Agency on Firecrawl Alexandria EU centralised medicines data from EMA's published data files: authorised medicines (EPAR pages), CHMP and CVMP opinions and withdrawn applications, applications under evaluation, EU orphan designations, EPAR and product documents, and EMA-assessed supply shortages, with EMA attribution on every result. - Categories: Life sciences - Category index: [Life sciences category](https://alexandria.firecrawl.dev/agents/categories/life-sciences) - Provider key: `ema-europa-eu` - Access: Firecrawl credits - Cost: 5 credits per call ## More - [Human guide](https://www.firecrawl.dev/app/alexandria/ema-europa-eu) - [OpenAPI spec](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/openapi.json) ## Capabilities - [Applications](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/applications): List applications for new human medicines under evaluation by EMA's CHMP, from EMA's monthly list: INN or common name, substance type, EMA product number, start of evaluation and flags for orphan, accelerated assessment, PRIME, OPEN and generic, hybrid or biosimilar. Use it for what EMA has under review before any opinion; month picks an earlier list (spreadsheets go back to February 2021). Indication summaries are withheld. Every result carries EMA attribution. - [Documents](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/documents): List EMA documents for centrally authorised medicines: EPAR public assessment reports, product information (SmPC and package leaflet), medicine overviews, variation reports, risk management plans, procedural steps and orphan maintenance reports, with type, first-published and last-updated dates and the PDF link, newest first. Find them by EMA product number or medicine name, narrow by type or date, and set language for a translated PDF link. Every result carries EMA attribution. - [Medicines](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/medicines): Search medicines evaluated through EMA's centralised procedure (EU EPAR medicine pages): name, EMA product number, status (Authorised, Withdrawn, Refused, ...), INN, active substance, ATC code, therapeutic area, marketing authorisation holder, procedure dates and flags such as orphan, generic, biosimilar and conditional approval. Filter by words, category or status, or resolve one ema_product_number. Therapeutic indications are withheld. Every result carries EMA attribution. - [Opinions](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/opinions): Search the outcomes of EMA's scientific committees on centralised applications: CHMP (human) and CVMP (veterinary) opinions on new marketing authorisations and on changes to authorised medicines, plus withdrawn applications, each dated, newest first. Filter by date range, outcome, procedure, product number or words; pending=true lists opinions not yet final (awaiting the European Commission decision or under re-examination). Every result carries EMA attribution. - [Orphan designations](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/orphan_designations): Search EU orphan designations: EU/3 designation number, active substance, the rare condition (intended use), status and designation or refusal date, with the authorised medicine that carries it, if any. Filter by words, status, linked EMA product number or designation date range. Look up one eu_designation_number or pasted designation page url to also get the sponsor and EMA's prevalence estimate at designation. Every result carries EMA attribution. - [Shortages](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/shortages): Search medicine supply shortages assessed by EMA: medicine, INN, status (Shortage ongoing, Shortage resolved, Medicine discontinued), pharmaceutical forms and strengths affected, availability of alternatives, expected resolution and the EMA shortage page. Filter by words, category or status, or resolve one record_id. Covers shortages EMA assessed, not every national shortage. Every result carries EMA attribution. ## 1. Choose this provider when EU centralised medicines data from EMA's published data files: authorised medicines (EPAR pages), CHMP and CVMP opinions and withdrawn applications, applications under evaluation, EU orphan designations, EPAR and product documents, and EMA-assessed supply shortages, with EMA attribution on every result. ## 2. Minimal request Call `POST https://api.firecrawl.dev/v2/scrape` with `{ alexandria: { provider, capability, options } }`. For a batch, send `{ alexandria: [...] }` with up to 10 calls. ```json { "provider": "ema-europa-eu", "capability": "records/applications", "options": { "limit": 3, "month": "2026-10" } } ``` ## 3. Add provider options Use only the options needed for the task: - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `ema_product_number` (string): Only this application, e.g. EMEA/H/C/006877. Not on the list is not_found. Pattern: ^EMEA/[HV]/C/[0-9]{6}$. Example: `` - `limit` (number): limit Example: `10` - `month` (string): Month of the list, YYYY-MM; defaults to the latest. A month without a spreadsheet list is not_found. Pattern: ^[0-9]{4}-[0-9]{2}$. Example: `` - `orphan` (boolean): true: only designated orphan medicines. Example: `false` - `query` (string): Words that must all appear, case-insensitive, in the INN, therapeutic area (lists before 2025) or product number, e.g. abatacept. Example: `` ## 4. Request through your preferred interface ### JavaScript ```javascript const result = await firecrawl.scrape({ alexandria: { provider: "ema-europa-eu", capability: "records/applications", options: { limit: 3, month: "2026-10", }, }, }); ``` ### Python ```python result = firecrawl.scrape_alexandria({ "provider": "ema-europa-eu", "capability": "records/applications", "options": { "limit": 3, "month": "2026-10" } }) ``` ### cURL ```sh curl https://api.firecrawl.dev/v2/scrape \ -H "Authorization: Bearer $FIRECRAWL_API_KEY" \ -H "Content-Type: application/json" \ -d '{ "alexandria": { "provider": "ema-europa-eu", "capability": "records/applications", "options": { "limit": 3, "month": "2026-10" } } }' ``` ### CLI ```sh firecrawl scrape 'ema-europa-eu/records/applications' \ --options '{"limit":3,"month":"2026-10"}' ``` ### MCP Call the FCX MCP retrieve tool with this object: ```json { "provider": "ema-europa-eu", "capability": "records/applications", "options": { "limit": 3, "month": "2026-10" } } ``` Ask for only the returned fields needed by the task. ## 5. Full request shape ```json { "provider": "ema-europa-eu", "capability": "records/applications", "options": { "limit": 3, "month": "2026-10" } } ``` ## 6. Response data The response includes `success`, `provider`, `capability`, `creditsCost` and `data`. This example shows the provider payload in `data`: ```json { "license": { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "name": "EMA legal notice", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "month": "2026-10", "next_cursor": "3", "observed_at_ms": 1793381388392, "records": [ { "accelerated_assessment": false, "ema_product_number": "EMEA/H/C/006741", "generic_hybrid_or_biosimilar": true, "inn": "Abatacept", "open": false, "orphan": false, "prime": false, "restarted_after_questions": null, "reverted_to_standard_timetable": null, "start_of_evaluation": "2026-06-18", "substance_type": "Biologicals", "therapeutic_area": null }, { "accelerated_assessment": false, "ema_product_number": "EMEA/H/C/007032", "generic_hybrid_or_biosimilar": true, "inn": "Abatacept", "open": false, "orphan": false, "prime": false, "restarted_after_questions": null, "reverted_to_standard_timetable": null, "start_of_evaluation": "2026-10-01", "substance_type": "Biologicals", "therapeutic_area": null }, { "accelerated_assessment": false, "ema_product_number": "EMEA/H/C/006857", "generic_hybrid_or_biosimilar": false, "inn": "Aceclidine", "open": false, "orphan": false, "prime": false, "restarted_after_questions": null, "reverted_to_standard_timetable": null, "start_of_evaluation": "2026-03-26", "substance_type": "Chemicals", "therapeutic_area": null } ], "source_updated_at": "2026-10-05", "source_url": "https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-october-2026_en.xlsx", "total_matching": 92, "withheld_fields": [ "indication_summary" ] } ``` ## API reference-derived contract The following capability contract is generated from the same normalized Alexandria API reference exposed in the API spec. ### Applications - Capability: `records/applications` - Description: List applications for new human medicines under evaluation by EMA's CHMP, from EMA's monthly list: INN or common name, substance type, EMA product number, start of evaluation and flags for orphan, accelerated assessment, PRIME, OPEN and generic, hybrid or biosimilar. Use it for what EMA has under review before any opinion; month picks an earlier list (spreadsheets go back to February 2021). Indication summaries are withheld. Every result carries EMA attribution. - Instructions: List applications for new human medicines under evaluation by EMA's CHMP, from EMA's monthly list: INN or common name, substance type, EMA product number, start of evaluation and flags for orphan, accelerated assessment, PRIME, OPEN and generic, hybrid or biosimilar. Use it for what EMA has under review before any opinion; month picks an earlier list (spreadsheets go back to February 2021). Indication summaries are withheld. Every result carries EMA attribution. - Cost: 5 credits per call - Capability file: [Applications](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/applications) Accepted options: - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `ema_product_number` (string): Only this application, e.g. EMEA/H/C/006877. Not on the list is not_found. Pattern: ^EMEA/[HV]/C/[0-9]{6}$. Example: `` - `limit` (number): limit Example: `10` - `month` (string): Month of the list, YYYY-MM; defaults to the latest. A month without a spreadsheet list is not_found. Pattern: ^[0-9]{4}-[0-9]{2}$. Example: `` - `orphan` (boolean): true: only designated orphan medicines. Example: `false` - `query` (string): Words that must all appear, case-insensitive, in the INN, therapeutic area (lists before 2025) or product number, e.g. abatacept. Example: `` Response schema example: ```json { "license": { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "name": "EMA legal notice", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "month": "2026-10", "next_cursor": "3", "observed_at_ms": 1793381388392, "records": [ { "accelerated_assessment": false, "ema_product_number": "EMEA/H/C/006741", "generic_hybrid_or_biosimilar": true, "inn": "Abatacept", "open": false, "orphan": false, "prime": false, "restarted_after_questions": null, "reverted_to_standard_timetable": null, "start_of_evaluation": "2026-06-18", "substance_type": "Biologicals", "therapeutic_area": null }, { "accelerated_assessment": false, "ema_product_number": "EMEA/H/C/007032", "generic_hybrid_or_biosimilar": true, "inn": "Abatacept", "open": false, "orphan": false, "prime": false, "restarted_after_questions": null, "reverted_to_standard_timetable": null, "start_of_evaluation": "2026-10-01", "substance_type": "Biologicals", "therapeutic_area": null }, { "accelerated_assessment": false, "ema_product_number": "EMEA/H/C/006857", "generic_hybrid_or_biosimilar": false, "inn": "Aceclidine", "open": false, "orphan": false, "prime": false, "restarted_after_questions": null, "reverted_to_standard_timetable": null, "start_of_evaluation": "2026-03-26", "substance_type": "Chemicals", "therapeutic_area": null } ], "source_updated_at": "2026-10-05", "source_url": "https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-october-2026_en.xlsx", "total_matching": 92, "withheld_fields": [ "indication_summary" ] } ``` ### Documents - Capability: `records/documents` - Description: List EMA documents for centrally authorised medicines: EPAR public assessment reports, product information (SmPC and package leaflet), medicine overviews, variation reports, risk management plans, procedural steps and orphan maintenance reports, with type, first-published and last-updated dates and the PDF link, newest first. Find them by EMA product number or medicine name, narrow by type or date, and set language for a translated PDF link. Every result carries EMA attribution. - Instructions: List EMA documents for centrally authorised medicines: EPAR public assessment reports, product information (SmPC and package leaflet), medicine overviews, variation reports, risk management plans, procedural steps and orphan maintenance reports, with type, first-published and last-updated dates and the PDF link, newest first. Find them by EMA product number or medicine name, narrow by type or date, and set language for a translated PDF link. Every result carries EMA attribution. - Cost: 5 credits per call - Capability file: [Documents](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/documents) Accepted options: - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `ema_product_number` (string): Only this medicine's documents, e.g. EMEA/H/C/000603. A number with no documents at all is not_found. Pattern: ^EMEA/[HV]/C/[0-9]{6}$. Example: `` - `language` (string): Adds translation_url, the document in this EU/EEA language, e.g. de. Example: `bg` - `limit` (number): limit Example: `10` - `published_from` (string): First published on or after this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `published_to` (string): First published on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `query` (string): Words that must all appear, case-insensitive, in the medicine name, product number or document title, e.g. Tysabri. Example: `` - `type` (string): Only this document type, e.g. assessment-report or product-information. Example: `product-information` - `updated_since` (string): Last updated on or after this date, YYYY-MM-DD; catches revised product information. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` Response schema example: ```json { "license": { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "name": "EMA legal notice", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "next_cursor": null, "observed_at_ms": 1793381386635, "records": [ { "ema_product_number": "EMEA/H/C/000603", "first_published": "2009-06-18T13:34:29Z", "languages": [ "bg", "cs", "da", "de", "el", "es", "et", "fi", "fr", "hr", "hu", "is", "it", "lt", "lv", "mt", "nl", "no", "pl", "pt", "ro", "sk", "sl", "sv" ], "last_updated": "2026-07-06T15:30:00Z", "medicine_name": "Tysabri", "reference_number": null, "source_url": "https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf", "title": "Tysabri : EPAR - Product information", "translation_url": "https://www.ema.europa.eu/de/documents/product-information/tysabri-epar-product-information_de.pdf", "type": "product-information", "type_label": "Product information (summary of product characteristics, labelling and package leaflet)" } ], "source_updated_at": "2026-10-30T17:52:04Z", "source_url": "https://www.ema.europa.eu/en/documents/report/documents-output-epar_documents_json-report_en.json", "total_matching": 1 } ``` ### Medicines - Capability: `records/medicines` - Description: Search medicines evaluated through EMA's centralised procedure (EU EPAR medicine pages): name, EMA product number, status (Authorised, Withdrawn, Refused, ...), INN, active substance, ATC code, therapeutic area, marketing authorisation holder, procedure dates and flags such as orphan, generic, biosimilar and conditional approval. Filter by words, category or status, or resolve one ema_product_number. Therapeutic indications are withheld. Every result carries EMA attribution. - Instructions: Search medicines evaluated through EMA's centralised procedure (EU EPAR medicine pages): name, EMA product number, status (Authorised, Withdrawn, Refused, ...), INN, active substance, ATC code, therapeutic area, marketing authorisation holder, procedure dates and flags such as orphan, generic, biosimilar and conditional approval. Filter by words, category or status, or resolve one ema_product_number. Therapeutic indications are withheld. Every result carries EMA attribution. - Cost: 5 credits per call - Capability file: [Medicines](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/medicines) Accepted options: - `category` (string): category Example: `Human` - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `ema_product_number` (string): Exact EMA product number, e.g. EMEA/H/C/000603. No match is not_found. Pattern: ^EMEA/[HV]/C/[0-9]{6}$. Example: `` - `limit` (number): limit Example: `10` - `query` (string): Words that must all appear, case-insensitive, in the medicine name, product number, INN, active substance, therapeutic area, ATC code or marketing authorisation holder, e.g. natalizumab. Example: `` - `status` (string): Exact medicine_status, case-insensitive, e.g. Authorised, Withdrawn, Refused, Lapsed, Expired, Revoked, Opinion, Application withdrawn. Example: `` Response schema example: ```json { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "data_timestamp": "2026-09-27T18:08:33Z", "dataset_records": 2746, "next_cursor": null, "observed_at_ms": 1790554594287, "records": [ { "data": { "accelerated_assessment": "No", "active_substance": "natalizumab", "additional_monitoring": "No", "advanced_therapy": "No", "atc_code_human": "L04AG03", "atcvet_code_veterinary": "", "biosimilar": "No", "category": "Human", "conditional_approval": "No", "ema_product_number": "EMEA/H/C/000603", "european_commission_decision_date": "18/06/2026", "exceptional_circumstances": "No", "first_published_date": "02/08/2018", "generic": "No", "international_non_proprietary_name_common_name": "natalizumab", "last_updated_date": "06/07/2026", "latest_procedure_affecting_product_information": "VR/0000314828", "marketing_authorisation_date": "27/06/2006", "marketing_authorisation_developer_applicant_holder": "Biogen Netherlands B.V.", "medicine_status": "Authorised", "medicine_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri", "name_of_medicine": "Tysabri", "opinion_adopted_date": "", "opinion_status": "", "orphan_medicine": "No", "patient_safety": "No", "pharmacotherapeutic_group_human": "Monoclonal antibodies", "pharmacotherapeutic_group_veterinary": "", "prime_priority_medicine": "No", "refusal_of_marketing_authorisation_date": "", "revision_number": "53", "species_veterinary": "", "start_of_evaluation_date": "", "start_of_rolling_review_date": "", "suspension_of_marketing_authorisation_date": "", "therapeutic_area_mesh": "Multiple Sclerosis", "withdrawal_expiry_revocation_lapse_of_marketing_authorisation_date": "", "withdrawal_of_application_date": "" }, "ema_product_number": "EMEA/H/C/000603", "medicine_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri", "name_of_medicine": "Tysabri" } ], "source_url": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json", "total_matching": 1, "withheld_fields": [ "therapeutic_indication" ] } ``` ### Opinions - Capability: `records/opinions` - Description: Search the outcomes of EMA's scientific committees on centralised applications: CHMP (human) and CVMP (veterinary) opinions on new marketing authorisations and on changes to authorised medicines, plus withdrawn applications, each dated, newest first. Filter by date range, outcome, procedure, product number or words; pending=true lists opinions not yet final (awaiting the European Commission decision or under re-examination). Every result carries EMA attribution. - Instructions: Search the outcomes of EMA's scientific committees on centralised applications: CHMP (human) and CVMP (veterinary) opinions on new marketing authorisations and on changes to authorised medicines, plus withdrawn applications, each dated, newest first. Filter by date range, outcome, procedure, product number or words; pending=true lists opinions not yet final (awaiting the European Commission decision or under re-examination). Every result carries EMA attribution. - Cost: 5 credits per call - Capability file: [Opinions](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/opinions) Accepted options: - `category` (string): category Example: `Human` - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `date_from` (string): Opinion or withdrawal on or after this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `date_to` (string): Opinion or withdrawal on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `ema_product_number` (string): Only this medicine, e.g. EMEA/H/C/005966. Pattern: ^EMEA/[HV]/C/[0-9]{6}$. Example: `` - `limit` (number): limit Example: `10` - `outcome` (string): outcome Example: `positive` - `pending` (boolean): true: only initial opinions awaiting the European Commission decision or under re-examination. Example: `false` - `procedure` (string): procedure Example: `initial` - `query` (string): Words that must all appear, case-insensitive, in the medicine name, product number, INN, active substance, therapeutic area, ATC code or applicant, e.g. lecanemab. Example: `` Response schema example: ```json { "license": { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "name": "EMA legal notice", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "next_cursor": null, "observed_at_ms": 1793381424839, "post_authorisation_source_url": "https://www.ema.europa.eu/en/documents/report/medicines-output-post_authorisation_json-report_en.json", "records": [ { "active_substance": "iloperidone", "applicant_or_holder": "Vanda Pharmaceuticals Netherlands B.V.", "atc_code": "N05AX14", "category": "Human", "committee": "CHMP", "date": "2026-02-26", "ema_product_number": "EMEA/H/C/006561", "flags": [], "inn": "iloperidone", "marketing_authorisation_date": null, "medicine_status": "Refused", "name_of_medicine": "Iloperidone Vanda Pharmaceuticals", "outcome": "negative", "pending": false, "procedure": "initial", "source_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/iloperidone-vanda-pharmaceuticals", "therapeutic_area": "Schizophrenia;Bipolar Disorder" } ], "source_updated_at": "2026-10-30T18:03:29Z", "source_url": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json", "total_matching": 1 } ``` ### Orphan designations - Capability: `records/orphan_designations` - Description: Search EU orphan designations: EU/3 designation number, active substance, the rare condition (intended use), status and designation or refusal date, with the authorised medicine that carries it, if any. Filter by words, status, linked EMA product number or designation date range. Look up one eu_designation_number or pasted designation page url to also get the sponsor and EMA's prevalence estimate at designation. Every result carries EMA attribution. - Instructions: Search EU orphan designations: EU/3 designation number, active substance, the rare condition (intended use), status and designation or refusal date, with the authorised medicine that carries it, if any. Filter by words, status, linked EMA product number or designation date range. Look up one eu_designation_number or pasted designation page url to also get the sponsor and EMA's prevalence estimate at designation. Every result carries EMA attribution. - Cost: 5 credits per call - Capability file: [Orphan designations](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/orphan_designations) Accepted options: - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `designated_from` (string): Designation or refusal on or after this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `designated_to` (string): Designation or refusal on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `ema_product_number` (string): Only designations linked to this authorised medicine, e.g. EMEA/H/C/004938. Pattern: ^EMEA/[HV]/C/[0-9]{6}$. Example: `` - `eu_designation_number` (string): Exact EU designation number, e.g. EU/3/18/2068. Adds sponsor and prevalence. No match is not_found. Pattern: ^EU/3/[0-9]{2}/[0-9]{1,5}$. Example: `` - `limit` (number): limit Example: `10` - `query` (string): Words that must all appear, case-insensitive, in the active substance, intended use (condition), medicine name or designation number, e.g. amyotrophic lateral sclerosis. Example: `` - `status` (string): Positive means currently designated. Example: `Positive` - `url` (string): EMA orphan designation page URL, e.g. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2068. Adds sponsor and prevalence. No match is not_found. Example: `` Response schema example: ```json { "license": { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "name": "EMA legal notice", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "next_cursor": null, "observed_at_ms": 1793381382375, "records": [ { "active_substance": "edaravone", "decision_date": "2015-06-19", "ema_product_numbers": [ "EMEA/H/C/004938" ], "eu_designation_number": "EU/3/15/1510", "first_published": "2015-07-27", "intended_use": "Treatment of amyotrophic lateral sclerosis", "last_updated": "2026-08-21", "medicine_names": [ "Radicava" ], "prevalence": "At the time of designation, ALS affected approximately 1 in 10,000 people in the European Union (EU).", "prevalence_per_10000": 1, "source_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1510", "sponsor": "Shionogi B.V.", "status": "Positive" } ], "source_updated_at": "2026-10-30T18:11:25Z", "source_url": "https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json", "total_matching": 1 } ``` ### Shortages - Capability: `records/shortages` - Description: Search medicine supply shortages assessed by EMA: medicine, INN, status (Shortage ongoing, Shortage resolved, Medicine discontinued), pharmaceutical forms and strengths affected, availability of alternatives, expected resolution and the EMA shortage page. Filter by words, category or status, or resolve one record_id. Covers shortages EMA assessed, not every national shortage. Every result carries EMA attribution. - Instructions: Search medicine supply shortages assessed by EMA: medicine, INN, status (Shortage ongoing, Shortage resolved, Medicine discontinued), pharmaceutical forms and strengths affected, availability of alternatives, expected resolution and the EMA shortage page. Filter by words, category or status, or resolve one record_id. Covers shortages EMA assessed, not every national shortage. Every result carries EMA attribution. - Cost: 5 credits per call - Capability file: [Shortages](https://alexandria.firecrawl.dev/agents/providers/ema-europa-eu/records/shortages) Accepted options: - `category` (string): category Example: `Human` - `cursor` (string): next_cursor from a previous page with the same filters. Pattern: ^[0-9]{1,6}$. Example: `` - `limit` (number): limit Example: `10` - `query` (string): Words that must all appear, case-insensitive, in the medicine affected, INN, therapeutic area or pharmaceutical form, e.g. immunoglobulins. Example: `` - `record_id` (string): record_id returned by this function, e.g. cerezyme. No match is not_found. Pattern: ^[a-z0-9-]{1,200}$. Example: `` - `status` (string): Exact supply_shortage_status, case-insensitive: Shortage ongoing, Shortage resolved or Medicine discontinued. Example: `` Response schema example: ```json { "attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice", "data_timestamp": "2026-09-27T18:15:40Z", "dataset_records": 85, "next_cursor": null, "observed_at_ms": 1790554594287, "records": [ { "data": { "availability_of_alternatives": "No", "category": "Human", "expected_resolution": "", "expected_resolution_date": "", "first_published_date": "04/11/2013", "international_non_proprietary_name_inn_or_common_name": "imiglucerase", "last_updated_date": "01/10/2018", "medicine_affected": "Cerezyme", "pharmaceutical_forms_affected": "Solution for infusion", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cerezyme", "start_of_shortage_date": "", "strengths_affected": "", "supply_shortage_status": "Shortage resolved", "therapeutic_area_mesh": "Gaucher Disease" }, "medicine_affected": "Cerezyme", "record_id": "cerezyme", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cerezyme" } ], "source_url": "https://www.ema.europa.eu/en/documents/report/shortages-output-json-report_en.json", "total_matching": 1 } ```